Two patient cases are presented here that illustrate the benefits of continuous dopaminergic stimulation on the non-motor symptoms of Parkinson's disease. In both cases, levodopa/carbidopa intestinal gel infusion therapy led to improvements in anxiety, depression, concentration, urge incontinence, sexual function, sleep, vivid dreams and rapid eye movement sleep behaviour disorder, pain, sweating and feelings of self-assuredness. Such improvements have an impact on patients' quality of life and can help their social functioning.
The non-motor symptoms (NMS) of Parkinson's disease (PD) are common and often not fully appreciated. They are sometimes referred to as non-dopaminergic symptoms, which in some cases may be a misnomer. NMS are present at all stages of the disease, and are potentially a major source of disability. Some of these symptoms, such as dementia, delirium, hallucinations, and psychosis, are important factors in PD patients' lives and may lead to institutionalisation. As such, they affect not only the individual but also have a social impact.
It is encouraging that the non-motor features of PD have been The following two case reports illustrate the impact of continuous dopaminergic stimulation (CDS) on the NMS and social aspects of PD.
Case Report 1
Patient 1, a 57-year-old male family physician, had been diagnosed with PD at the age of 45. After 12 years of PD, his daily regimen was 800 mg levodopa (spread over seven intakes) plus 100 mg levodopa-benserazide hydrodynamically balanced system (HBS). He also took 200 mg tolcapone (three times a day), 100 mg amantadine (twice daily), 1 mg rasagiline (once daily) and 150 mg venlafaxine (once daily). Table 1 ).
After the patient started LCIG infusion therapy, there was an evolution in his clinical motor presentation. His morning 'off' improved and he no longer had unpredictable 'off' or delayed 'on'. The patient had suffered from stuttering in childhood, which had improved when he was a young man but had returned with the onset of PD. It was particularly troublesome during 'off' periods. After beginning LCIG infusion treatment, he reported that the stuttering improved significantly. The patient's dyskinesia was also improved. One year after initiating LCIG infusion therapy, the duration and disability of dyskinesia were reduced and pain was eliminated (see Table 2 ).
Additionally, there were improvements in a range of NMS (anxiety, depression, urge incontinence, feeling self-assured and sexual dysfunction) and the patient was able to return to work full-time.
These were improvements that the patient considered as being the most important in his life.
Case Report 2
Patient 2, a 52-year-old male administrator in health insurance, had been diagnosed with PD at 40 years of age, but the first sign of tremor had actually appeared at the age of 30. was slightly increased at six months, from 1.9 to 2.2 ml/h, which was not a concern (see Table 3 ). After six months, the patient did not have a morning dose because he used the pump 24 hours a day. At one year, he was on 2.9 ml/h during the waking day and at midnight, the dose was reduced to 2.6 ml/h. An extra dose of 1.6 ml was used a few times a week, mostly post-prandial.
The patient's motor symptoms improved after beginning LCIG infusion therapy. His morning 'off', unpredictable 'on-off' fluctuations and delayed 'on' were all eliminated. There was substantial improvement in his dyskinesias: their duration was reduced from 2 to 1 as assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) and they were no longer disabling (UPDRS disability score was reduced from 3 to 0). There were also improvements in various NMS (depression, anxiety, concentration, sleep, sexual dysfunction, pain, sweating, and vivid dreams and RBD), and the patient was able to work full-time again.
Non-motor Symptoms in Parkinson's Disease
NMS are recognised as an integral part of PD. However, they remain misdiagnosed and untreated in many patients, which is an issue given that the appearance of non-motor manifestations often represents a milestone in the disease trajectory, and can indicate a worse prognosis and lower quality of life (QoL).
The NMS complex of PD (see Box 2) changes over the course of the disease. 2 There is compelling evidence that sleep disturbances (e.g., RBD), 3 It is increasingly recognised that gait dysfunction, freezing and postural instability are multifactorial, involving an interaction of motor and non-motor mechanisms. 8 Cognition also plays a role in freezing and, as a result of these symptoms, falls are common in advanced Parkinson's disease (APD) and are a leading cause of morbidity and mortality in this population. For example, the frequency of fractures is doubled in PD patients compared with age-matched controls. 9 Falls can also lead to placement in a nursing home.
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• Psychiatric disorders or disturbances assessment -at least annually
• Cognitive impairment or dysfunction assessment -at least annually
• Querying about symptoms of autonomic dysfunction -at least annually
• Querying about sleep disturbances -at least annually
• Querying about falls -all visits Morning dose 3.0 ml 3.0 ml 3.0 ml
Continual dose 1.6 ml/h 1.8 ml/h 1.5 ml/h Extra dose 1.0 ml 1.0 ml 1.0 ml The cognitive and neuropsychiatric symptoms of PD can also result in admission to a nursing home. They range from anxiety, apathy and depression to dementia, some of which may be part of the disease process itself, but may also be aggravated by medications and co-morbidities.
These cognitive and neuropsychiatric symptoms could also occur in response to having a chronic progressive illness and, in this context, may be improved by anti-Parkinson's medications, as seen in the two patient cases discussed above. In these two patients, CDS therapy with LCIG infusion also resulted in improvements in other NMS, such as sleep disorders, autonomic symptoms and sensory symptoms.
Prospective Study on Non-motor Symptoms in Parkinson's Disease
In a prospective study on genotype-phenotype correlations in 139 PD patients (mean age 68 years ± 10.4, mean age of disease onset 60.5 years and mean disease duration 7.5 years ± 6.2), our group showed a high prevalence of NMS (the median number of NMS per patient was nine). 10 The most common were urinary urgency, nocturia and sleeping problems. A higher number of reported NMS was associated with a longer disease duration and clinical features that suggested more advanced disease, such as motor fluctuations, dyskinesias, dementia and postural instability. The study results also showed that disease progression, rather than age, was associated with a greater number of reported NMS. Furthermore, our group showed a weak correlation between the number of reported NMS and UPDRS motor score.
However, these results are likely confounded by medication use. The two case reports presented in this article illustrate the impact of CDS treatment in PD. By increasing dopaminergic tone through LCIG infusion treatment, the two patients' motor performance was improved and their NMS were considerably reduced. Thus, CDS therapy has greatly improved these patients' lives and, by allowing them to return to work full-time, has also had an important social impact. n
Conclusions

